<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-19T01:56:18Z</responseDate><request verb="GetRecord" identifier="oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/15376" metadataPrefix="oai_dc">https://ebyu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/15376</identifier><datestamp>2026-10-18T20:30:11Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_ebyu_10000</setSpec><setSpec>col_ebyu_10001</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>The molecular mechanism involved in the protective effect of etodolac against ovarian injury induced with ischemia/reperfusion in rats</dc:title><dc:creator>Al, Ragip A.</dc:creator><dc:creator>Yapca, Omer E.</dc:creator><dc:creator>Dogan, Hasan</dc:creator><dc:creator>Mammadov, Renad</dc:creator><dc:creator>Altuner, Durdu</dc:creator><dc:creator>Suleyman, Bahadir</dc:creator><dc:creator>Cetin, Nihal</dc:creator><dc:subject>Etodolac</dc:subject><dc:subject>IL-1β</dc:subject><dc:subject>Ischemia/reperfusion</dc:subject><dc:subject>Rat</dc:subject><dc:subject>TNF-α</dc:subject><dc:subject>interleukin 1beta</dc:subject><dc:subject>myeloperoxidase</dc:subject><dc:subject>superoxide dismutase</dc:subject><dc:subject>tumor necrosis factor alpha</dc:subject><dc:subject>animal model</dc:subject><dc:subject>animal tissue</dc:subject><dc:subject>Article</dc:subject><dc:subject>controlled study</dc:subject><dc:subject>DNA synthesis</dc:subject><dc:subject>female</dc:subject><dc:subject>gene expression</dc:subject><dc:subject>ischemia</dc:subject><dc:subject>nonhuman</dc:subject><dc:subject>ovarian injury</dc:subject><dc:subject>ovary disease</dc:subject><dc:subject>real time polymerase chain reaction</dc:subject><dc:subject>reperfusion injury</dc:subject><dc:description>This study investigated the protective effect at the molecular level of etodolac against ovarian injury induced in rats with ischemia/reperfusion (I/R). Rats were divided into four groups. The 25 mg/kg etodolac + ovarian ischemia/reperfusion (EIR 25) and 50 mg/kg etodolac+ovarian ischemia/reperfusion (EIR 50) groups were given etodolac by the oral route 1 h before administration of anesthesia. Two h of ischemia and 2 h of reperfusion were applied to ovarian tissue in all groups (except for (SG) sham operation group) 1 h after etodolac administration. The experimental results showed that etodolac at a dose of 50 mg/kg suppressed MPO (myeloperoxidase), TNF-α, IL-1β gene expression in ovarian tissue with I/R better than at a dose of 25 mg/kg. In addition, etodolac at these doses prevented a decrease in SOD gene expression in ovarian tissue subjected to I/R to a significant extent (p &lt; 0.0001). In conclusion, etodolac can be used in the treatment of I/R-related ovarian injury. © 2015, Colegio de Farmaceuticos de la Provincia de Buenos Aires. All rights reserved.</dc:description><dc:publisher>Colegio de Farmaceuticos de la Provincia de Buenos Aires</dc:publisher><dc:date>2015</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/ebyu/15376</dc:identifier><dc:identifier>0326-2383</dc:identifier><dc:language>en</dc:language><dc:relation>Latin American Journal of Pharmacy</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/15376</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>